Pfizer buys biotech group for $ 5.2 bi to stimulate innovation

Pfizer closed deal to acquire biotech group Anacor, Silicon Valley, for $ 5.2 billion, to stimulate the creative side of their business before a possible breakup next year.
The cash offer was approved by the boards of both companies and assesses the Anacor, headquartered in Palo Alto, at $ 99.25 per share — a premium of about 55% of the share price on Friday, before the movement caused by the offer.
On Monday, shares of Anacor soared in 54%, to $ 98.42, before the opening of trading, and Pfizer have not changed.
The Anacor was founded in 2002 to develop technologies created by the universities Stanford and Pennsylvania, and specializes in creating medications using the chemical element boron, preferably to more traditional carbon-based compounds.
One of his medicines — a ointment called Crisaborole — is being reviewed by the Food and Drug Administration (FDA, the federal agency that regulates and oversees food and medicine), for the treatment of a type of eczema hard to control.
The remedy must be approved in January, after presenting good performance in two large clinical trials, and could generate annual sales of more than $ 2 billion, at the peak of the market, according to Pfizer.
"The acquisition of Anacor represents an attractive opportunity to meet a significant medical need and subatendida to a large population of patients suffering from mild to moderate Atopic Dermatitis, and at the moment there are many topical treatments available," said Albert Bourla, President of Global Innovative Pharma Division of Pfizer.
Atopic dermatitis is a common type of eczema that causes rash and affects between 18 million and 25 million people in the United States. Pfizer said he believed that the disease was significantly under-diagnosed disease "because of the limitations of existing treatments. There hasn''t been a new drug approved to treat her for the past 15 years.
Pfizer announced that the acquisition of Anacor Bank with their reserves and that in 2017 should be earnings per share "slightly diluted", but that from 2018 the profits would be expanded.
Last month, taking control of Allergan, headquartered in Dublin, by Pfizer, in a transaction worth $ 160 billion, was blocked by the Obama Government, in an effort to prevent the company transferring its tax domicile to Ireland in order to save billions of dollars in taxes in the United States.
Since then, Pfizer has returned to its "plan A" and accelerated the schedule to decide whether to split into two companies — one focused on new and innovative drugs and another to operate with the older drugs whose patents are for expires.
The company expects to decide by the end of the year, paving the way for a split in the beginning of 2017.
Some investors and analysts predicted that Pfizer will acquire several pharmaceutical manufacturers, this year in order to fatten the innovative side of its operations before cindi it.
Pfizer also expressed interest in acquiring the Medivation, a San Francisco company that specializes in fighting cancer, according to people involved in the negotiations. The Medivation is evaluating bids after the French pharmaceutical group Sanofi made a hostile takeover attempt of controlling interest in April, for $ 9.3 billion.